Evaluation of Warfarin Use in Cardiac Clinic Outpatients

Norisca A. Putriana,¹ Taofik Rusdiana,¹ Tina Rostinawati,² Mohammad R. Akbar,³ Dika P. Destiani,⁴ Afifah L. Wahyuningtyas⁴

¹Department of Pharmaceutical and Formulation Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang District, West Java - Indonesia
²Department of Biology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang District, West Java - Indonesia
³Department of Cardiovascular, Faculty of Medicine, Universitas Padjadjaran, Sumedang District, West Java - Indonesia
⁴Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang District, West Java - Indonesia

Abstract

The use of warfarin was monitored using the International Normalized Ratio (INR) value. This study aims to determine the relationship between the patient’s demographic variables and INR, as well as the therapy result and differences in their INR value. A cross-sectional study was used with retrospective observational data collected by tracing secondary information of medical records from outpatients with heart disease on warfarin therapy at Dr. Hasan Sadikin hospital Bandung between 2016 to 2020. Subsequently, the difference in patients’ INR value was analyzed with the Mann-Whitney test based on dosage. At the same time, the relationship between demographic variables and INR was examined using the Chi-square test and Spearman correlation. The INR examination results in 192 subjects showed 124 patients (64.6%) reached the target with an average value of 2.37 ± 0.21 and a warfarin dose of 19.31 ± 6.25 mg weekly, while 68 (35.4%) had an average of 1.82 ± 0.73 and a dose of 20.24 ± 6.24 mg weekly. Subsequently, the difference test with Mann Whitney (p = 0.004) showed a variation in the INR value based on the warfarin dose. The Spearman correlation analysis results indicated a relationship between BMI (p = 0.009), daily (0.010), and weekly dose (0.008) on the INR value with the correlation coefficient of 0.188; 0.186; and 0.192; indicating a negative association with very weak correlation strength. This study showed that a majority of patients reached the INR value of 2-3, and the demographic variables associated with this ratio were BMI and warfarin dose. The decision to increase and decrease the warfarin dose is determined by INR value and BMI.

Keywords: warfarin, dose, INR, outpatients
**Introduction**

World Health Organization (WHO) stated that about 17.9 million deaths occurred globally due to heart disease in 2016. This condition occurs due to impaired function and blood vessels and consists of coronary and rheumatic heart disorder, cerebrovascular disease, and other conditions.¹ According to Riskesdas data, the 2018 prevalence of heart disease in Indonesia was 1.5%.²

Consequently, anticoagulants are drugs that prevent the blood clotting process by inhibiting fibrin formation. One of the most common anticoagulants is warfarin, which is widely used to treat or prevent thromboembolism-related diseases, including stroke, heart attack, embolism, atrial fibrillation, and deep vein thrombosis. This drug is still widely used even after six decades.³,⁴

Warfarin has a narrow therapeutic index, which indicates that a slight dose difference causes a significant alteration in response. Therefore, administration of a large dose increases the bleeding risk, while a small quantity will cause failure in the treatment or prevention of thromboembolism. Since drug doses vary widely between patients and must be individualized, dosage adjustment is necessary and would lead to variations in its use. This variability is due to age, gender, ethnicity, anticoagulant indication, vitamin intake, body weight, albumin levels, and drugs consumed.³ Anticoagulant status during warfarin use was monitored with INR, where the most common target value was between 2 to 3. Also, patient INR values are examined every 4 to 6 weeks for dose adjustment until it is stabilized.⁵,⁶

In Lithuania, a study on warfarin showed the INR value for patients with atrial fibrillation was out of the target range by more than half (57.3%), where approximately 40% of cases occur because the subjects do not evaluate and adjust the dose.⁷ Patient knowledge of warfarin therapy is still low, although the level of adherence is high.⁸ Our study showed, most warfarin therapy has not reached the therapeutic INR range of 2 to 3.⁹ Also, a study by Megawati et al., 2019 evaluating this drug use showed that only 27% of patients achieved the target range.¹⁰ Consequently, INR monitoring can improve its stability within the therapeutic range and prevent serious complications.¹¹

Based on the background described above, an evaluation of warfarin use in heart disease patients at Dr. Hasan Sadikin Hospital was conducted to determine the drug use profile, effectiveness, and if the administered therapy dose has reached the target therapeutic INR value of 2 to 3. Dispensation of safe and effective warfarin doses improves the therapy’s success and patient’s life quality and avoids side effects of bleeding.

**Methods**

**Study Design**

This is a cross-sectional study with retrospective observational data collected by searching secondary information in medical records from outpatients with heart disease at Dr. Hasan Sadikin Hospital between January 2016 and December 2020. The obtained data included gender, age, height, weight, disease diagnosis, warfarin dose, duration of warfarin use, comorbidities, other drugs used concurrently, and INR values. Subsequently, the information was processed and analyzed statistically. This study has been approved by the Ethics Commission of Universitas Padjadjaran, Bandung, Indonesia (No. 28/UN6. KEP/EC/2021).

**Study Subject**

The study subjects included all medical records from heart disease outpatients who used oral warfarin anticoagulants in Dr. Hasan Sadikin
Hospital between January 2016 to December 2020. Also, patients were required to have used this drug for a minimum of one month and have measured the INR value at least once. The exclusion criteria were incomplete and untraceable medical record data.

**Statistical Analysis**

Descriptive analyses were used to represent subjects’ demographic data, including gender, age, Body Mass Index (BMI), warfarin indication, and amount of it. The Mann-Whitney test was used to compare differences in INR values based on daily warfarin doses. Meanwhile, Chi-Square and Spearman methods were used to determine the relationship between the parameters. The analysis was performed using SPSS software with a p-value <0.05 for significant results.

**Table 1. Characteristics of Respondent**

| Characteristics | N  | (%) |
|-----------------|----|-----|
| **Gender**      |    |     |
| Male            | 92 | 47.9|
| Female          | 100| 52.1|
| **Age (Year)**  |    |     |
| 15-24           | 5  | 2.6 |
| 25-34           | 10 | 5.2 |
| 35-44           | 32 | 16.7|
| 45-54           | 54 | 28.1|
| 55-64           | 55 | 28.6|
| 65-74           | 28 | 14.6|
| >75             | 8  | 4.2 |
| **BMI**         |    |     |
| Under weight (<18.5) |12 | 6.3 |
| Normal (18.5-24.9) |128| 66.7|
| Pre-Obesity (25.0-29.9) |39 | 20.3|
| Obesity (>30)   | 13 | 6.8 |
| **Warfarin Indicator** |    |     |
| AF              | 100| 52.1|
| CAD             | 2  | 12.0|
| DVT             | 1  | 0.5 |
| RHD             | 68 | 35.4|
| **Number of Drugs** |    |     |
| <5              | 102| 53.1|
| >5              | 90 | 46.9|

**Table 2. The Use of Warfarin Dose**

| Warfarin (mg/week) | N  | (%) |
|--------------------|----|-----|
| 7 mg               | 1  | 0.5 |
| 12 mg              | 14 | 7.3 |
| 14 mg              | 22 | 11.5|
| 16 mg              | 29 | 15.1|
| 18 mg              | 27 | 14.1|
| 20 mg              | 30 | 15.6|
| 21 mg              | 14 | 7.3 |
| 23 mg              | 13 | 6.8 |
| 25 mg              | 8  | 4.2 |
| 27 mg              | 13 | 6.8 |
| 29 mg              | 9  | 4.7 |
| 31 mg              | 4  | 2.1 |
| 33 mg              | 4  | 2.1 |
| 36 mg              | 2  | 1.0 |
| 45 mg              | 1  | 0.5 |
| 50 mg              | 1  | 0.5 |
Results and Discussion
In this study, 192 medical records were obtained from patients who had and are currently using warfarin anticoagulant therapy. Furthermore, the respondents’ treatments were monitored with INR examination. The results included data on respondent characteristics, patient INR values, warfarin dose, and the relationship between respondent characteristics and INR.

Characteristics of Respondents
Based on the data, the average age was 53 years, and 52.1% of the patients were female. Most patients who received warfarin were diagnosed with Atrial Fibrillation (AF) (52.1%) and Rheumatic Heart Disease (RHD) (35.4%), while a total of 53.1% received less than five other drugs. Moreover, the warfarin dose in each individual varies because it is usually adjusted with the patient’s condition and INR value. (Table 1) Furthermore, the majority of patients were given 20 mg of weekly warfarin dosage (15.6%). (Table 2)

Reached and Unreached INR Values in Patients
Warfarin therapy was monitored using INR values for dose adjustment. This process was conducted daily or at intervals of the initial treatment. In this study, patients had a monthly INR check, where the recommended target for most warfarin indications is between 2 to 3 but varies per individual condition. About 124 patients (64.6%) had achieved the target INR (mean: 2.37 ± 0.21). The warfarin dose is considered to affect the INR value. Hence the amount administered to the patients is usually adjusted. Comparative analysis of the drug quantity in the group of patients with reached and unachieved INR values with Mann-Whitney (p < 0.05) provided insignificant results (p = 0.282); hence there was no difference in warfarin dose between the two groups. (Table 3)

Patients who achieve the target INR use daily and weekly doses are maintained until the INR value was checked in the next month. If the INR value was still ideal, the amount was continued. The daily and weekly doses should be changed if the result was below or above the ideal INR value. Patients who did not reach the target INR, the dose of warfarin should be adjusted for one month and then re-evaluated by looking at the INR value.

Data Analysis of The Relationship Between Respondents Characteristics and INR
The respondents’ characteristics related to the patient’s INR value are BMI (p = 0.009) and warfarin dose (p < 0.05) are presented in Table 4.

Several studies on the evaluation of warfarin use monitored through INR values have been conducted. A report by Mansur et al., 2012, 80% of AF patients aged >65 years have

| INR Achievement       | Number of Patients | INR Value (mean ± SD) | Warfarin Dose (mg/weeks) (mean ± SD) | P value |
|-----------------------|--------------------|-----------------------|--------------------------------------|---------|
| Target INR Achieved   | 124                | 2.37 ± 0.21           | 19.31 ± 6.25                         |         |
| Target INR Unachieved | 68                 | 1.82 ± 0.73           | 20.24 ± 6.24                         | 0.282   |
| Total                 | 22                 |                       | 11.5                                 |         |
achieved the INR target of 2 to 3 with warfarin dose of 2 to 5 mg/day.12 Another study showed that most patients (N= 124 patients; 64.6%) reached the target, while 54 patients (62.79%) failed.13 Therefore, dose adjustments with good enough patient adherence to warfarin consumption were conducted based on the INR value for those who reached the target.

The success of warfarin therapy can also be achieved with the role of pharmacists. Our previous study showed that counseling from the professionals significantly influences the patient’s knowledge and perception of the treatment.14 Furthermore, education and comprehensive counseling on this therapy, including risks, benefits, and drug and food interactions, are considered essential components to achieving warfarin therapy success.

Low patient knowledge about warfarin and medical personnel education is why some individuals did not reach the INR target,15 where limited knowledge of the drug’s indications is associated with non-adherence to the therapy.16 In this study, there was no difference in the daily dose of warfarin in the group of patients with reached and unreached INR. The result is in line with the study by Furdiyanti et al., 2014, which gave insignificant findings.13 Therefore, the patient’s response to warfarin therapy may vary. However, the same dose is administered because the treatment is influenced by factors such as age, gender, comorbidities, adherence, and changes in diet or alcohol consumption.17

This study showed a significant difference in INR values based on warfarin dose (p=0.004). Consequently, patients with different amounts provided therapeutic results in the form of varying INR values due to clinical, non-clinical, and genetic factors.18 Warfarin dose-response is unpredictable in every patient. Therefore, monitoring the INR daily during the initiation phase, weekly after reaching the desired target, and monthly after the value is stable is recommended.19

Warfarin dose-response is influenced by age, BMI, nutritional status, comorbid disease, drug interactions, pharmacogenetics, and ethnicity.20 Therefore, monitoring the drug with INR is an essential factor affecting warfarin therapy’s suitability.21 The factors associated with INR values in this study included BMI (p = 0.009), daily (p = 0.010), and a weekly dose of warfarin (0.008). However, other respondent characteristics, such as gender,
drug interactions, comorbidities, and age, were not associated with INR ($p > 0.05$).

BMI is thought to affect the weekly dose of warfarin, but the results are insignificant. Hence the effect of this factor on determining the drug dose requirements is still unclear.\textsuperscript{22} According to Mueller et al., 2014, patients with high BMI require a high Total Weekly Dose (TWD) of warfarin to maintain a stable therapeutic INR. The results of this study indicate that there is a relationship between BMI and INR ($p = 0.009$) with a correlation coefficient of $-0.188$ (very weak).\textsuperscript{23} Also, a study by Ogunsua et al., 2015 showed that obesity class II (BMI 35-39.9 kg/m\textsuperscript{2}) and III (>40 kg/m\textsuperscript{2}) significantly increased the risk of major bleeding compared to patients with normal weight. In addition, obese patients on this therapy took longer to reach the therapeutic INR time than the non-obese. Moreover, the risk of bleeding increased in patients with a high INR value greater than 3.\textsuperscript{24}

The INR value in warfarin therapy is influenced by its dose, where the risk of bleeding and thromboembolism increases and decreases with the dose, respectively.\textsuperscript{3} However, warfarin dose-response to INR value varies for each individual; hence regularly adjusting the dose to the patient is necessary. The results of Spearman analysis showed a significant relationship between the daily ($p = 0.010$; $\rho = -0.186$) and weekly dose ($p = 0.008$; $\rho = -0.192$) with INR value.

A study by Khairunnisa et al., 2013.\textsuperscript{25} showed a significant relationship between dose and INR in ischemic stroke patients with atrial fibrillation. According to Mansur et al., 2012, elderly patients with chronic atrial fibrillation also showed a relationship between these two factors with a $p$-value and correlation of 0.012 and 0.22, respectively.\textsuperscript{12}

Also, genetic polymorphism is a factor that influences warfarin therapy, where the genes that affect the response to this treatment, including CYP2C9 and VKORC1. CYP2C9 plays a role in the drug’s metabolism, which is associated with slower warfarin metabolism and a longer time to reach a stable INR value. At the same time, VKORC1 is the site gene for encoding VKORs related to the drug’s sensitivity.\textsuperscript{20,26} However, the analysis of the relationship between genetic polymorphisms and INR was not performed in this study because there was no genetic data in the patient’s medical record, although genetics is a factor that affects the determination of the warfarin dose and patient’s INR value.

This study’s limitations include the location, which was restricted. Hence further investigations are expected to add this factor to obtain a larger patient number. In addition, only medical record data was used without considering other factors that influence the response to warfarin therapy, such as food interactions, genetic polymorphisms, and smoking habits.

**Conclusion**

Most patients have reached the target INR value of 2 to 3, and factors that affect the INR value are BMI and warfarin dose.

**Acknowledgment**

The authors gratefully acknowledge the generous grant from The Indonesian Ministry of Education Directorate General of Higher Education (DIKTI) that made this study possible.

**Funding**

-

**Conflict of Interest**

The authors declared no conflict of interest in the manuscript
References

1. World Health Organization. Cardiovascular Disease 2020. https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1 (accessed on 7 September 2020)
2. Ministry of Health Republic of Indonesia. Riset Kesehatan Dasar (Risksdas) 2018, Indonesian Health Research and Development Agency, Jakarta 2018.
3. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and Its Interaction with Foods, Herbs, and Other Dietary Supplements. Expert Opinion on Drug Safety. 2006; 5(3): 433-451.
4. Pellagatti T, Ternelli M, Frascio D, Bettini R. Warfarin Personalized Dosage: Re-compounding for a More Suitable Therapy and Better Compliance. International Journal of Pharmaceutical Compounding. 2017; 21 (3): 247-250.
5. Galus AS, Baker RI, Chong BH, Ockelford PA. Consensus Guidelines for Warfarin Therapy. The Medical Journal of Australia. 2000; 172 (12): 600-605.
6. Johnson JA. Warfarin Pharmacogenetics: A Rising Tide for Its Clinical Value. Circulation. 2012; 125 (16): 1964-1966.
7. Urbonas G, Valius L, Sakalyte G, Petniunas K, Petniuniene I. The Quality of Anticoagulant Therapy Among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting. Medicina. 2019; 55 (15): 11-11.
8. Shuaib W, Ifikhar H, Alweis R, Shahid H. Warfarin Therapy: Survey of Patients Knowledge of Their Drug Regimen. Malaysian Journal of Medical Sciences. 2014; 21 (4): 37-41.
9. Putriana NA, Lestari K, Diantini A, Rusdiana T. Warfarin Therapy Monitoring of Cardiac Care Patients in Hospital in Bandung. Jurnal Farmasi Klinik Indonesia. 2012; 1 (3): 110-116.
10. Megawati S, Lestari T, Setyani WL. Evaluation of The Use Warfarin Oral on The INR Value of The Pathway Patients RSU of Kabupaten Tangerang in 2018. Farmagazine. 2019; 6 (2): 10-16.
11. Kasinathan G, Pairan S, Rowther S, Sulaiman S, Basimin SA, Samsuni N, Balasegar V. Efficacy of Point-of-Care Testing (POCT) in Reducing Total Waiting Time at Warfarin Clinic of a District Hospital: A Cohort Study. Open Access Library Journal. 2016; 3 (2): 1-7.
12. Mansur AP, Takada JY, Avakian SD, Strunz CMC. Warfarin Dose for Anticoagulation Therapy in Elderly Patients with Chronic Atrial Fibrillation. Clinics. 2012; 67 (6): 543-546.
13. Furdiyanti NH, Pramantara IDP, Wahyono D. Evaluation of Warfarin Dosing and Its Clinical Outcome in Outpatients. Jurnal Manajemen dan Pelayanan Farmasi. 2014; 4 (3): 175-179.
14. Putriana NA, Barliana MI, Lestari K. The Influence of Pharmacist’s Counseling on Knowledge and Perception on Cardiac Patient Warfarin Management at Dr. Hasan Sadikin Hospital Bandung. Jurnal Farmasi Klinik Indonesia. 2017; 6 (4): 282-289.
15. Baker JW, Pierce KL, Ryals CA. INR Goal Attainment and Oral Anticoagulation Knowledge of Patients Enrolled in an Anticoagulation Clinic in a Veterans Affairs Medical Center. The Journal of Managed Care and Specialty Pharmacy. 2011; 17 (2): 133-42.
16. Park R, Koo SM, Hwang MO, Seo DC, Kim KU,Uh ST, Kim YK. Feasibility of Warfarin Anticoagulation Management with a Patient Self-Testing Model in Korea. Clinical and Experimental Thrombosis and Hemostatis. 2015; 2 (1): 8-10.
17. Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, et al. Comparison of Initial Warfarin Response in Obese Patients Versus Non-
Obese Patients. *Journal of Thrombosis and Thrombolysis*. 2013; 36: 96-101.

18. Yin T, Miyata T. Warfarin Dose and The Pharmacogenomic of CYP2C9 and VKORC1 Rational and Perspective. *Thrombosis Research*. 2007; 120 (1): 1-10.

19. Njovane XW, Fasinu PS, Rosenkranz B. Comparative Evaluation of Warfarin Utilisation in Two Primary Healthcare Clinics in The Cape Town Area. *Cardiovascular Journal of Africa*. 2013; 24 (2): 19-23.

20. White PJ. Patient Factors That Influence Warfarin Dose Response. *Journal of Pharmacy Practice*. 2010; 23 (3): 194-204.

21. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic Overview of Warfarin and Its Drug and Food Interactions. *Archive of Internal Medicine*. 2005; 165 (10): 1095-106.

22. Whitely HP, Fermo JD, Chumney EC, et al. Effect of Patient-Specific Factors on Weekly Warfarin Dose. Ther Clin Risk Manag. 2007; 3 (3): 499-504.

23. Mueller JA, Patel T, Halawa A, Dumitrascu A, Dawson NL. Warfarin Dosing and Body Mass Index. *Annals of Pharmacology*. 2014; 48 (5): 584-588.

24. Ogunsua AA, Touray S, Lui JK, Ip T, Escobar JV, Gore J. Body Mass Index Predicts Major Bleeding Risks in Patients on Warfarin. *Journal of Thrombosis and Trombolysis*. 2015; 40 (4): 494-498.

25. Khairunnisa D, Sari IP, Gofir A. The Correlation Between Dose and Duration in Warfarin Administration Against INR (International Normalized Ratio) Target 1.5-2.0 on Ischemic Stroke Patient with Atrial Fibrillation. *Jurnal Manajemen dan Pelayanan Farmasi*. 2013; 3 (4): 269-272.

26. Yoshizawa M, Hayashi H, Tashiro Y, Sakawa S, Moriwari H, Akimoto T, et al. Effect of VKORC1-1639 DNA Polymorphism, Body Weight, Age, and Serum Albumin Alterations on Warfarin Response in Japanese Patients. *Thrombosis Research*. 2009; 124 (2): 161-166.